NASDAQ: SGMTSagimet Biosciences Inc Stock
$5.92+0.07 (+1.2%)
Updated Dec 31, 2025
SGMT Price
$5.92
Fair Value Price
$2.42
Market Cap
$192.53M
52 Week Low
$1.73
52 Week High
$11.41
P/E
-3.33x
P/B
1.61x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$57.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.08
Operating Cash Flow
-$45M
Beta
2.11
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SGMT Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SGMT's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SGMT
Ranked#325 of 490
Ranked#325 of 490
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $17.67 | A | |
| $15.95 | A | |
| $397.65 | A |
Be the first to know about important SGMT news, forecast changes, insider trades & much more!
SGMT News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SGMT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SGMT ($5.92) is overvalued by 144.97% relative to our estimate of its Fair Value price of $2.42 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SGMT ($5.92) is not significantly undervalued (144.97%) relative to our estimate of its Fair Value price of $2.42 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SGMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SGMT due diligence checks available for Premium users.
Valuation
SGMT fair value
Fair Value of SGMT stock based on Discounted Cash Flow (DCF)
Price
$5.92
Fair Value
$2.42
Overvalued by
144.97%
SGMT ($5.92) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SGMT ($5.92) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SGMT is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SGMT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.33x
Industry
145.82x
Market
43.84x
SGMT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.61x
Industry
5.26x
SGMT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SGMT's financial health
Profit margin
Revenue
$0.0
Net Income
-$12.9M
Profit Margin
0%
SGMT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$128.4M
Liabilities
$9.1M
Debt to equity
0.08
SGMT's short-term assets ($119.48M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SGMT's short-term assets ($119.48M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SGMT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.2M
Investing
$75.0k
Financing
$274.0k
SGMT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SGMT vs Biotech Stocks
Sagimet Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.